TY - JOUR
T1 - Quality of life in sarcopenia measured with the SarQoL questionnaire
T2 - A meta-analysis of individual patient data
AU - Beaudart, Charlotte
AU - Tilquin, Noémie
AU - Abramowicz, Pawel
AU - Baptista, Fátima
AU - Peng, Dao Juan
AU - de Souza Orlandi, Fabiana
AU - Drey, Michael
AU - Dzhus, Marta
AU - Fábrega-Cuadros, Raquel
AU - Fernandez-Garrido, Julio
AU - Laurindo, Lucas Fornari
AU - Gasparik, Andrea Ildiko
AU - Geerinck, Anton
AU - Emin, Gyulnaz
AU - Iacob, Speranta
AU - Kilaitė, Justina
AU - Kumar, Prabal
AU - Lee, Shu Chun
AU - Lou, Vivian W.Q.
AU - Mahmoodi, Marzieh
AU - Matijevic, Radmila
AU - Matveeva, Mariia V.
AU - Merle, Blandine
AU - Montero-Errasquín, Beatriz
AU - Bhattoa, Harjit Pal
AU - Safonova, Yuliya
AU - Şimşek, Hilal
AU - Topinkova, Eva
AU - Tsekoura, Maria
AU - Erdoğan, Tuğba
AU - Yoo, Jun Il
AU - Yu, Ruby
AU - Hiligsmann, Mickael
AU - Reginster, Jean Yves
AU - Bruyère, Olivier
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2024/2
Y1 - 2024/2
N2 - Age-related sarcopenia, resulting from a gradual loss in skeletal muscle mass and strength, is pivotal to the increased prevalence of functional limitation among the older adult community. The purpose of this meta-analysis of individual patient data is to investigate the difference in health-related quality of life between sarcopenic individuals and those without the condition using the Sarcopenia Quality of Life (SarQoL) questionnaire. A protocol was published on PROSPERO. Multiple databases and the grey literature were searched until March 2023 for studies reporting quality of life assessed with the SarQoL for patients with and without sarcopenia. Two researchers conducted the systematic review independently. A two-stage meta-analysis was performed. First, crude (mean difference) and adjusted (beta coefficient) effect sizes were calculated within each database; then, a random effect meta-analysis was applied to pool them. Heterogeneity was measured using the Q-test and I2 value. Subgroup analyses were performed to investigate the source of potential heterogeneity. The strength of evidence of this association was assessed using GRADE. From the 413 studies identified, 32 were eventually included, of which 10 were unpublished data studies. Sarcopenic participants displayed significantly reduced health-related quality of life compared with non-sarcopenic individuals (mean difference = −12.32; 95 % CI = [−15.27; −9.37]). The model revealed significant heterogeneity. Subgroup analyses revealed a substantial impact of regions, clinical settings, and diagnostic criteria on the difference in health-related quality of life between sarcopenic and non-sarcopenic individuals. The level of evidence was moderate. This meta-analysis of individual patient data suggested that sarcopenia is associated with lower health-related quality of life measured with SarQoL.
AB - Age-related sarcopenia, resulting from a gradual loss in skeletal muscle mass and strength, is pivotal to the increased prevalence of functional limitation among the older adult community. The purpose of this meta-analysis of individual patient data is to investigate the difference in health-related quality of life between sarcopenic individuals and those without the condition using the Sarcopenia Quality of Life (SarQoL) questionnaire. A protocol was published on PROSPERO. Multiple databases and the grey literature were searched until March 2023 for studies reporting quality of life assessed with the SarQoL for patients with and without sarcopenia. Two researchers conducted the systematic review independently. A two-stage meta-analysis was performed. First, crude (mean difference) and adjusted (beta coefficient) effect sizes were calculated within each database; then, a random effect meta-analysis was applied to pool them. Heterogeneity was measured using the Q-test and I2 value. Subgroup analyses were performed to investigate the source of potential heterogeneity. The strength of evidence of this association was assessed using GRADE. From the 413 studies identified, 32 were eventually included, of which 10 were unpublished data studies. Sarcopenic participants displayed significantly reduced health-related quality of life compared with non-sarcopenic individuals (mean difference = −12.32; 95 % CI = [−15.27; −9.37]). The model revealed significant heterogeneity. Subgroup analyses revealed a substantial impact of regions, clinical settings, and diagnostic criteria on the difference in health-related quality of life between sarcopenic and non-sarcopenic individuals. The level of evidence was moderate. This meta-analysis of individual patient data suggested that sarcopenia is associated with lower health-related quality of life measured with SarQoL.
KW - Health-related quality of life
KW - Individual-patient data meta-analysis
KW - Sarcopenia
KW - SarQoL
UR - http://www.scopus.com/inward/record.url?scp=85181041039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181041039&partnerID=8YFLogxK
U2 - 10.1016/j.maturitas.2023.107902
DO - 10.1016/j.maturitas.2023.107902
M3 - Review article
C2 - 38142467
AN - SCOPUS:85181041039
SN - 0378-5122
VL - 180
JO - Maturitas
JF - Maturitas
M1 - 107902
ER -